Jacobs Levy Equity Management’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Jacobs Levy Equity Management’s Portfolio SGTX Stock Details SGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-10,983	Closed	-$394K	–	1112
2021 Q4	$394K	Buy	+10,983	New	+$625K	﹤0.01%	864
2021 Q3	–	Sell	-5,084	Closed	-$709K	–	1155
2021 Q2	$709K	Buy	+5,084	New	+$893K	﹤0.01%	807

Other funds holding SGTX

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jacobs Levy Equity Management's SGTX Position: Q1 2022 in Review

Jacobs Levy Equity Management sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q1 2022, closing a stake of 10,983 shares — an estimated $394K sold.

Jacobs Levy Equity Management first reported a position in SGTX in Q2 2021 and held it in 2 quarters. The position peaked at $709K in Q2 2021. 48 funds tracked by Wall St. Rank hold SGTX as of Q1 2022.

Jacobs Levy Equity Management reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Jacobs Levy Equity Management sold 10,983 Sigilon Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $394K.
Jacobs Levy Equity Management first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
Jacobs Levy Equity Management's Sigilon Therapeutics, Inc. Common Stock position peaked at $709K in Q2 2021.
48 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2022, filed 16 May 2022.